Beijing University of Chinese Medicine, Beijing, 100102, China.
Xiyuan Hospital of China Academy of Chinese Medical Sciences, 100091, China.
J Ethnopharmacol. 2021 Oct 28;279:114386. doi: 10.1016/j.jep.2021.114386. Epub 2021 Jul 3.
Esophageal cancer, as a high incidence of gastrointestinal cancer, has an indelible impact on human life and health. The combination of Chinese herbal injections and chemotherapy is commonly applied in the treatment of Esophageal cancer.
This study aimed to confirm the clinical advantage of Compound Kushen Injection to treat esophageal cancer and explore its molecular mechanism.
The network meta-analysis method was used for the clinical evaluation of anti-tumor Chinese herbal injections. Initially, several electronic databases were searched to identify randomized controlled trials regarding Chinese herbal injections to treat esophageal cancer from their inception to September 5, 2020. Then, WinBugs and Stata software was used to calculate and analyze the outcome indicators, including total clinical efficiency, improvement of quality of life and adverse reactions. Furthermore, the surface under the cumulative ranking curve and three-dimensional cluster analysis were used to rank the efficacy and safety of Chinese herbal injections about each outcome. Cell Counting Kit-8 assay was used to observe the effect of Compound Kushen Injection on the proliferation of esophageal cancer cells. Real-Time Quantitative PCR and Western Blot analysis were used to detect the mRNA and protein expression of EGFR and AURKA in ESCA cells.
The surface under the cumulative ranking curve of Compound Kushen Injection combined with chemotherapy in total clinical efficiency, quality of life, reduction of nausea and vomiting were ranking at 89.1%, 81.8% and 92.4%, respectively. Compound Kushen Injection was determined as the dominant variety in the treatment of esophageal cancer which can inhibit the proliferation of esophageal cancer cells and downregulate the overexpression of EGFR and AURKA mRNA and protein.
In this study, network meta-analysis was applied to confirm that Compound Kushen Injection has a curative effect on esophageal cancer and is superior to other anti-tumor Chinese herbal injections. Combined with the network pharmacology and in vitro experiment, the mechanism of Compound Kushen Injection inhibiting the proliferation of esophageal cancer cells by regulating the abnormal expression of EGFR and AURKA was revealed.
食管癌作为一种高发的胃肠道癌症，对人类的生命和健康有着不可磨灭的影响。中药注射剂与化疗联合应用于食管癌的治疗中。
本研究旨在证实复方苦参注射液治疗食管癌的临床优势，并探讨其分子机制。
采用网络荟萃分析方法对抗肿瘤中药注射剂的临床疗效进行评价。首先，检索了多个电子数据库，以确定从成立到 2020 年 9 月 5 日期间治疗食管癌的中药注射剂随机对照试验。然后，使用 WinBugs 和 Stata 软件计算和分析总临床疗效、生活质量改善和不良反应等结局指标。此外，采用累积排序曲线下面积和三维聚类分析对每种结局的中药注射剂的疗效和安全性进行排序。使用细胞计数试剂盒-8 法观察复方苦参注射液对食管癌细胞增殖的影响。实时定量 PCR 和 Western blot 分析用于检测 ESCA 细胞中 EGFR 和 AURKA 的 mRNA 和蛋白表达。
复方苦参注射液联合化疗在总临床疗效、生活质量、减少恶心呕吐方面的累积排序曲线下面积分别为 89.1%、81.8%和 92.4%。复方苦参注射液在食管癌的治疗中被确定为优势品种，能够抑制食管癌细胞的增殖，并下调 EGFR 和 AURKA mRNA 和蛋白的过表达。
本研究通过网络荟萃分析证实了复方苦参注射液对食管癌具有治疗作用，且优于其他抗肿瘤中药注射剂。结合网络药理学和体外实验，揭示了复方苦参注射液通过调节 EGFR 和 AURKA 的异常表达抑制食管癌细胞增殖的作用机制。
